Why the study?
The study was conducted to compare the clinical effectiveness of dalteparin and enoxaparin for thromboprophylaxis in patients undergoing elective total hip or knee replacement.
Does dalteparin compared to enoxaparin improve safety and reduce bleeding in adult patients undergoing elective total hip or knee replacement?
RCT (n=66)
Does dalteparin compared to enoxaparin improve safety and reduce bleeding in adult patients undergoing elective total hip or knee replacement?
Answers are grounded in this paper and cite their sources.
In patients undergoing major orthopedic surgery, enoxaparin may be associated with greater blood loss and higher rates of red blood cell infusion compared to dalteparin.
Aim To compare the clinical effectiveness of the two most commonly used LMWHs, dalteparin (DALT) and enoxaparin (ENOX), in thromboprophylaxis of elective total hip replacement (THR) or total knee replacement (TKR). Material and methods To the prospective, randomized study were included 66 adult patients qualified to undergo THR or TKR (age 63 ± 12 years, 44 women). The patients were randomized to daily in-hospital subcutaneous prophylaxis with 5,000 I.U. of DALT or 40 mg of enoxaparin. Clinical and laboratory data were collected before surgery, and on 1st and 5th days after surgery. Results Thirty-four patients were randomized to prophylaxis with ENOX and 32 with DALT. The groups did not differ significantly in age, sex, creatinine and most of the laboratory parameters. The compared groups had similar surgical parameters, but more patients in the ENOX group received red blood cell infusion (17(50%) vs 8(25%); p < 0.05). The Lee–White coagulation time mildly decreased in ENOX and DALT following the surgery (p = ns). There was a shortening of Duke’s bleeding time in DALT after the surgery and it became significantly quicker than that in ENOX on Day 5 (p = 0.03). Conclusion The observed difference in Duke’s bleeding time and exceeding blood loss during the surgery on the enoxaparin demands confirmation, as it can be important information for clinical management.
No takes yet. Share an insight, caveat, or question.
Biławicz et al. (2020) conducted an RCT in elective total hip replacement (THR) or total knee replacement (TKR) (n=66). Dalteparin vs. Enoxaparin 40 mg daily subcutaneous was evaluated on red blood cell infusion (p=< 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: